A carregar...
Switching treatments in haemophilia: is there a risk of inhibitor development?
Patients with haemophilia A (and their physicians) may be reluctant to switch factor VIII (FVIII) concentrates, often due to concerns about increasing the risk of inhibitors; this reluctance to switch may contribute to patients missing the clinical benefits provided by the arrival of new factor VIII...
Na minha lista:
| Publicado no: | Eur J Haematol |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BlackWell Publishing Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4407931/ https://ncbi.nlm.nih.gov/pubmed/25135593 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.12433 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|